The clinical significance of tissue polypeptide antigen in breast cancer patients.
TPA levels in patients with primary or metastatic breast cancer were determined. The rate of TPA elevations in patients with local recurrence and metastatic breast cancer was determined from follow-up studies. The control group included healthy persons and patients with benign diseases of the breast. The diagnostic sensitivity was influenced mainly by the disease stage. The sensitivity increased from 4% at stage I to 66% at stage IV. The sensitivity in patients with local recurrence was 23%, and 82% in patients with progressive metastatic breast cancer. These data are based on a reference range of 0-120 U/L TPA, which was calculated from the healthy control group and the benign disease group at a specificity level of 95%.
Mross
K
K
Bandlow
G
G
D001943:Breast Neoplasms / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010455:Peptides / Q000032:analysis*; D019396:Tissue Polypeptide Antigen
D002272:Carcinoembryonic Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen